Cure My Disease

Don't miss your cure!

 Log in / Sign up

New test could make diagnosis of thirst disorders easier for patients

NCT ID NCT07569861

Diagnosis Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a new diagnostic test using mannitol infusion to the standard hypertonic saline test for diagnosing the cause of polyuria-polydipsia syndrome (excessive urination and thirst). Researchers will enroll 144 adults to see if the mannitol test is as accurate and more comfortable for patients. The goal is to find a simpler way to diagnose conditions like arginine vasopressin deficiency and primary polydipsia.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mannitol and hypertonic saline (diagnostic agents)
What this could lead to
If successful, this could provide a simpler, more comfortable diagnostic test for people with excessive thirst and urination, replacing the current standard test.
What could go wrong
This is a relatively small, early-phase diagnostic study. The mannitol test may not be as accurate as the standard test, and results may not apply to all patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 144 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years 2. Hypotonic polyuria/polydipsia syndrome defined as polyuria \>40ml/kg body weight/24h and polydipsia \>3l/24h; and urine osmolality \<800mOsm/L or known AVP-D based on accepted criteria Exclusion Criteria: 1. Polyuria/polydipsia secondary to diabetes mellitus, hypercalcemia, or hypokalemia 2. Diagnosis of AVP-R (Copeptin \> 21.4 pmol/L) 3. Evidence of acute illness 4. Epilepsy requiring treatment 5. Uncontrolled arterial hypertension (blood pressure \>160/100mmHg at baseline 6. eGFR \< 60 ml/min/1,73 m2 7. Cardiac failure (NYHA III-IV) 8. Diagnosis of liver cirrhosis, Child-Pugh Class C 9. Uncorrected adrenal or thyroidal deficiency 10. Pregnancy or breastfeeding 11. Current or unresolved urinary obstruction 12. Enrollment in a clinical trial within the last 30 days 13. Patients refusing or unable to give written informed consent 14. Inability to follow study procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arginine vasopressin deficiency are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes insipidus Diabetes Insipidus, Neurogenic neurohypophyseal diabetes insipidus Polydipsia, Psychogenic primary polydipsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arginine vasopressin deficiency Primary polydipsia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital Basel

    RECRUITING

    Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.